Evidence map›Paper›PMID 40970519›Full record

ReviewImmunotherapy2025

The potential of phytomedicines to optimize CAR-T cell therapy in cancer.

Ángela Covo-Vergara, Uxue Díez De Ulzurrun-Ripa, Cristian Smerdou, Mercedes Hernández-Rueda, Delia G Estrada-Palafox, Claudia Ureña, Sandra Hervas-Stubbs, Susana Fiorentino, Maritza R Garcia-Garcia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ángela Covo-VergaraImmunology and Immunotherapy Program, Cima Universidad de Navarra, Pamplona, Spain.
Uxue Díez De Ulzurrun-RipaImmunology and Immunotherapy Program, Cima Universidad de Navarra, Pamplona, Spain.
Cristian SmerdouInstituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Mercedes Hernández-RuedaImmunology and Immunotherapy Program, Cima Universidad de Navarra, Pamplona, Spain.
Delia G Estrada-PalafoxEscuela de Nutrición, Universidad Autónoma de Guadalajara, Zapopan, Jalisco, Mexico.
Claudia UreñaGrupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Sandra Hervas-StubbsImmunology and Immunotherapy Program, Cima Universidad de Navarra, Pamplona, Spain.
Susana FiorentinoGrupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Maritza R Garcia-GarciaImmunology and Immunotherapy Program, Cima Universidad de Navarra, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has revolutionized oncology therapeutics landscape. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, a form of adoptive cell therapy (ACT) designed to target and kill cancer cells, has shown remarkable success in the treatment of hematological cancer. However, its efficacy against solid tumors remains limited. Phytomedicines represent promising adjuvants to overcome current limitations in cancer immunotherapy due their active compounds that can regulate immune cell functions, modulate immune checkpoint pathways, and reshape the tumoral microenvironment (TME). Current research investigating the TME-modulating effects of certain phytomedicines supports their potential integration as immunotherapy adjuvants. This review focuses on phytomedicines with demonstrated anticancer and immunomodulatory properties, some of which are currently being tested in clinical trials for cancer patients. Despite this promise, significant hurdles persist in the development of phytomedicines as reliable adjuvants in cancer immunotherapy. Consequently, rigorous and focused research is essential to validate their efficacy and safety in this context.

Indexed as

Immunotherapy, AdoptiveNeoplasmsPhytochemicalsReceptors, Chimeric AntigenT-LymphocytesAdjuvants, ImmunologicAnimalsHumansTumor MicroenvironmentAdjuvants, ImmunologicPhytochemicalsReceptors, Chimeric AntigenCAR-T cellsHibiscus SabdariffaImmunotherapyPetiveria alliaceaphytomedicinesPiper nigrumQYSLS

Identifiers

PMID40970519
PMCPMC12582054

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.